Literature DB >> 27559190

Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.

Limin Gao, Jivin Joseph, Marcelle Santoro-Levy, Alan S Multz, Vladimir K Gotlieb.   

Abstract

BACKGROUND: With the advances in cancer treatments, mortality rates in the United States have been consistently falling but they are accompanied by substantial increases in the cost of cancer care. Patient and prescription assistance programs (PPAPs) are offered by pharmaceutical manufacturers to provide free medications to medically indigent patients. To assist the Cancer Care Center (CCC) at Nassau University Medical Center (NUMC) with drug costs for chemotherapies, the pharmacy department uses a patient assistance program (PAP) to obtain medications from the drug companies at no cost.
PURPOSE: This study evaluates the impact of the PAP at a public hospital from which indigent cancer patients obtain assistance for chemotherapy.
METHODS: We followed all patients requiring assistance with chemotherapy who enrolled in the PAP from January 1, 2011 through December 31, 2012. Medications included both oral and parenteral chemotherapy drugs and antiemetics used in the outpatient clinic setting.
RESULTS: The program served 347 patients in 2011 and 579 patients in 2012. The total number of visits in the clinic over 24 months was 9,405. The total cost savings of the medications was $1,066,000 in 2011 and $1,715,538 in 2012.
CONCLUSIONS: A pharmacy-based PAP to procure free medications from PPAPs for cancer patients has helped to defray the expense of providing care at NUMC, increased patients' compliance with chemo protocols, and allowed many patients to receive the treatment they otherwise would not be able to afford. The combination of PPAPs and PAP provides a safety net to ensure that indigent cancer patients receive needed prescription medications in the outpatient clinic setting.

Entities:  

Keywords:  cancer patients; patient and prescription assistance program; patient assistance program

Year:  2016        PMID: 27559190      PMCID: PMC4981105          DOI: 10.1310/hpj5107-572

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  27 in total

1.  Use of drug manufacturers' patient assistance programs by safety net providers.

Authors:  Katheryne Richardson; Lorne E Basskin
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

2.  Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs.

Authors:  Patrick Clay; Eric Vaught; Alan Glaros; Stacy Mangum; Daniel Hansen; Cameron Lindsey
Journal:  J Manag Care Pharm       Date:  2007 Jul-Aug

3.  National health spending in 2013: growth slows, remains in step with the overall economy.

Authors:  Micah Hartman; Anne B Martin; David Lassman; Aaron Catlin
Journal:  Health Aff (Millwood)       Date:  2014-12-03       Impact factor: 6.301

4.  Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors.

Authors:  Hrishikesh P Kale; Norman V Carroll
Journal:  Cancer       Date:  2016-03-14       Impact factor: 6.860

5.  Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails.

Authors:  Philip E Johnson
Journal:  Am J Health Syst Pharm       Date:  2006-11-01       Impact factor: 2.637

6.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.

Authors:  Sonya Blesser Streeter; Lee Schwartzberg; Nadia Husain; Michael Johnsrud
Journal:  Am J Manag Care       Date:  2011-05       Impact factor: 2.229

7.  Pharmaceutical manufacturer assistance programs.

Authors:  Marie A Chisholm; Joseph T DiPiro
Journal:  Arch Intern Med       Date:  2002-04-08

8.  Pharmaceuticals companies' medication assistance programs: potentially useful but too burdensome to use?

Authors:  Maria Pisu; Joshua Richman; Jeroan J Allison; O Dale Williams; Catarina I Kiefe
Journal:  South Med J       Date:  2009-02       Impact factor: 0.954

9.  Evaluation of trends in the cost of initial cancer treatment.

Authors:  Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

10.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

View more
  3 in total

1.  Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

Authors:  Adam J Olszewski; Andrew R Zullo; Christopher R Nering; Justin P Huynh
Journal:  J Oncol Pract       Date:  2018-02-13       Impact factor: 3.840

2.  Cost savings analysis of prescription assistance programs at a student-run free clinic.

Authors:  Nathan Chow; Annie Snitman; John Rafael; Stephanie Bui; Kelly Bennett; Fiona Prabhu
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-01-18

3.  Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.

Authors:  Megan E V Caram; Shikun Wang; Phoebe Tsao; Jennifer J Griggs; David C Miller; Brent K Hollenbeck; Paul Lin; Bhramar Mukherjee
Journal:  Urol Pract       Date:  2019-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.